Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK4 | Q16654 | 1/20 | 0.51 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.50 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 9/20 | 0.49 |
| ▸ | GRM5 | P41594 | 8/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CDK7 | P50613 | 1/20 | 0.42 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.42 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25167744 | 1.00 | PDK4 (0.51) | PDK4DDB1CRBNGRM1GRM5 | |
| SCHEMBL23120656 | 0.89 | NAMPT (0.52) | PDK4DDB1CRBNGRM1GRM5 | |
| SCHEMBL29225363 | 0.84 | DDB1 (0.51) | DDB1CRBN | |
| SCHEMBL31444234 | 0.84 | PDK4 (0.51) | PDK4DDB1CRBNGRM1GRM5 | |
| SCHEMBL30952401 | 0.83 | NAMPT (0.47) | PDK4DDB1CRBNGRM1GRM5 | |
| SCHEMBL31201927 | 0.83 | PDK4 (0.46) | PDK4DDB1CRBNGRM1GRM5 | |
| SCHEMBL29223732 | 0.83 | PDK4 (0.46) | PDK4DDB1CRBNGRM1GRM5 | |
| SCHEMBL24319286 | 0.83 | GRM1 (0.47) | PDK4DDB1CRBNGRM1GRM5 | |
| SCHEMBL3988457 | 0.80 | PDK4 (0.56) | PDK4GRM1GRM5NAMPTCDK7 | |
| SCHEMBL7831576 | 0.80 | PDK4 (0.58) | PDK4GRM1GRM5NAMPTCDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | UBIX THERAPEUTICS, INC. (KR) | 2025-02-06 | — | — | US | disclosed |
| EP-4428130-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | Ubix Therapeutics, Inc. (KR) | 2024-09-11 | — | — | EP | disclosed |
| CN-118159532-A | Compound with BTK protein degradation activity and medical application thereof | 尤比克斯治疗公司 | 2024-06-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041429-A1 | COMPOUND HAVING BTK PROTEIN DEGRADATION ACTIVITY, AND MEDICAL USES THEREOF | BTK, LYN, SYK | PDK4 2906/4885DDB1 1245/4885CRBN 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.